PhD Scientific Days 2025

Molecular Medicine II.

Sugammadex activates neutrophilic granulocytes – explanation of a side effect

Előadó neve

Nagy Mátka

Neptun code

G0SOAU

Előadó munkahelye

Department of Physiology, Faculty of Medicine, Semmelweis University, Hungary

Előadó telefonszáma

+36307790850

Előadó e-mail címe

nagy.matka@gmail.com

Az előadás címe

Sugammadex activates neutrophilic granulocytes – explanation of a side effect

Szerző(k) neve és munkahelye

Mátka Nagy¹, Ákos M. Lőrincz^1,2, Tamás Sohajda³, Balázs Kondoros³

1: Department of Physiology, Faculty of Medicine, Semmelweis University, Hungary
2: Second Department of Internal Medicine, Szent György Hospital, Székesfehérvár, Hungary
3: CarboHyde Zrt, Budapest, Hungary

Bemutatás módja

Szóbeli

Szekció

Molecular Medicine II.

Language of the presentation

English

Preferred session

Molecular Medicine

Összefoglaló szövege

Introduction
Cyclodextrins (CDs) are cyclic oligosaccharides widely used in the pharmaceutical industry
due to their ability to enhance the solubility, stability, and bioavailability of various drugs.
Beyond traditional applications, some CDs are used as active ingredients. These substances
may influence immune responses by modulating immune cell behavior. Sugammadex, a
modified gamma-cyclodextrin, is commonly used to reverse neuromuscular blockade induced
by rocuronium during surgery. Recently, safety concerns have been raised regarding the
potential of sugammadex inducing anaphylactic reactions.
Aims
The aim of this study was to investigate the potential effects of CDs on leukocyte functions.
Methods
Leukocytes were isolated from healthy adult donors in accordance with the Declaration of
Helsinki and with ethics approval from ETT TUKEB (31937-7/202/EÜIG). We evaluated
several derivatives used in various commercial pharmaceutical products. Cell viability of
neutrophils, monocytes, and lymphocytes was assessed by annexin V and propidium iodide
staining via flow cytometry (FC). Basal, opsonized zymosan-, and PMA-induced reactive
oxygen species (ROS) production was measured by chemiluminescence assay, basal and LPSstimulated IL-8 secretion by ELISA, and CD11b expression by FC.
Results
CDs did not alter immune cell viability at therapeutic concentrations; however, higher
concentrations slightly reduced cell viability and count. Sugammadex had no effect on basal
ROS production but markedly increased opsonized zymosan-induced ROS production in
neutrophils and monocytes. It also significantly elevated both basal and LPS-stimulated IL-8
secretion, as well as CD11b expression on neutrophils.
Other CDs moderately affected neutrophil functions, with minimal impact on monocytes.
Conclusion
These findings suggest that sugammadex induces neutrophil priming and activation, which
may contribute to inflammatory responses and reported anaphylactic events. Further studies
are needed to evaluate these effects in animal models and in clinical settings following
sugammadex administration.
Funding
2024-2.1.2-EKÖP-KDP-2024-00002.
The author acknowledges funding from the European Union's Horizon Europe Research and
Innovation Programme under the Marie Sklodowska-Curie grant agreement Bicyclos no.
101130235.
EFOP-3.6.3-VEKOP-16-2017-00009, NKFIH FK 137770, TKP2021-EGA-24.

University

Semmelweis University

Supervisor

Ákos M. Lőrincz

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies before complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

8248

Start

10:15

End

10:30